SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is experiencing market pressure after its CagriSema obesity drug did not achieve non-inferiority against Eli Lilly's competitor in a recent trial, fueling community debate over its competitive standing. However, strong early demand for its oral Wegovy, coupled with recent regulatory actions against compounded GLP-1 alternatives and ongoing share buybacks, is leading many to see the current sell-off as an overreaction and a potential buying opportunity.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for BYSANTI, a new chemical entity with patent protection extending to 2044 for bipolar I disorder and schizophrenia. Community sentiment is largely bullish on significant upside potential and a possible short squeeze, though some express caution regarding a recent shelf offering and the drug's similarity to an existing therapy.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Recent positive clinical data for Arcellx's multiple myeloma CAR-T therapy, anito-cel, showcases strong efficacy and a differentiated safety profile, driving current conversation. An expanded strategic partnership and investment from Kite (Gilead), combined with the recent lifting of a partial clinical hold, reinforces market confidence and highlights the company's competitive edge in the cell therapy landscape.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting stellar Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, demonstrating high efficacy and potential disease-modifying effects. This positive data, coupled with a major institutional investor significantly increasing its stake and an anticipated Investor Day, has ignited strong community discussion about its "best-in-class" potential, a potential re-rating, and a short squeeze.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as its Mainnet recently went live and a partnership with Aplix for a Japan-regulated stablecoin was announced, alongside its inclusion in Coinbase's institutional index for perpetual futures. This has sparked a polarized community discussion, with proponents highlighting these fundamental advancements for long-term potential, while critics remain skeptical given the token's continued price performance.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community debate intensifies around recent tariff rulings and new global levies, with widespread discussion focusing on their economic impact and concerns over the company's financial stability and potential dilution ahead of upcoming disclosures.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Dominos Pizza is drawing attention after its Q4 earnings report showcased solid results and strategic investments, further amplified by Berkshire Hathaway's increased stake. The community is actively debating if its focus on value and digital initiatives can continue to drive market share in a competitive restaurant environment.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as Novo Nordisk's latest obesity drug trial underperformed Eli Lilly's, reigniting community discussion that Viking's competitive dual agonist VK2735 is now a highly attractive acquisition or partnership target for pharmaceutical giants eager to capture market share.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending as the community processes its solid Q4 earnings beat against conservative 2026 guidance, alongside significant M&A activity including the Arcellx acquisition and key patent settlements for its dominant HIV franchise. Investors are also closely watching developments in its oncology pipeline, such as recent Trodelvy trial results, amid discussions about the company's long-term growth trajectory in a volatile market.

Freshpet, Inc. engages in the manufacturing, marketing, and distribution of pet food and pet treats for dogs and cats. Its products are blends of fresh meats, vegetables, and fruits farmed locally and made at Freshpet kitchens. Its products include Deli Fresh Grain Free Chicken Recipe for Dogs, Joy Turkey and Apple Bites Treats, Nature's Fresh Grain Free Chicken Recipe for Cats, and Vital Grain Free Chicken and Ocean Whitefish Recipe for Cats. The company was founded by Scott Morris and Cathal Walsh in November 2004 and is headquartered in Bedminster, NJ.

Freshpet Inc

Freshpet is trending due to impressive earnings that showed strong growth and positive future projections, fueling community discussion around its market leadership in the premium pet food category. Despite ongoing debates about its valuation and past corporate governance concerns, analysts are largely optimistic, issuing numerous price target increases and highlighting the company's consistent expansion and improving profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Promising Automotive Stocks To Watch Today - February 21st

O'Reilly Automotive, AutoZone, Monolithic Power Systems, Illinois Tool Works, Keysight Technologies, Rivian Automotive, and Genuine Parts are the seven Automotive stocks to watch today, according to...

Electric Vehicle Stocks To Watch Now - February 20th

Tesla, Rivian Automotive, BorgWarner, NIO, and QuantumScape are the five Electric Vehicle stocks to watch today, according to MarketBeat's stock screener tool. Electric vehicle stocks are shares of...

Automotive Stocks To Follow Today - February 20th

O'Reilly Automotive, AutoZone, Rivian Automotive, Monolithic Power Systems, and Keysight Technologies are the five Automotive stocks to watch today, according to MarketBeat's stock screener tool...

Vanguard Group Inc. Boosts Position in Rivian Automotive, Inc. $RIVN

Vanguard Group Inc. grew its holdings in shares of Rivian Automotive, Inc. (NASDAQ:RIVN - Free Report) by 3.3% in the 3rd quarter, according to the company in its most recent disclosure with the...

Why Rivian Stock Sank This Week

Key PointsRivian expects a sharp rise in EV deliveries this year...

Stevens Capital Management LP Takes $1.28 Million Position in Rivian Automotive, Inc. $RIVN

Stevens Capital Management LP purchased a new stake in Rivian Automotive, Inc. (NASDAQ:RIVN - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities...

Rivian Automotive (NASDAQ:RIVN) Shares Down 2.1% - Here's What Happened

Rivian Automotive (NASDAQ:RIVN) Shares Down 2.1% - Time to Sell...

Rivian Shares Surged on Delivery Forecast. Is It Too Late to Buy the Stock?

Key PointsRivian shares shot higher on strong delivery guidance...

Elon Musk's Net Worth Is So Large He Could Buy Ford, GM, Rivian And Toyota And Still Have $141 Billion Left

Elon Musk's net worth continues to rise in 2026 thanks to the merger of SpaceX and xAI. Here's how Musk's net worth compares to Tesla rival companies.read more...

Here is What to Know Beyond Why Rivian Automotive, Inc. (RIVN) is a Trending Stock

Rivian Automotive (RIVN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive (RIVN) stock price, news, forum, discussion, financials, community insights, and trading ideas, Join 10 million+ investors and traders tracking markets in real-time on Stocktwits

RIVN: Rivian Stock Price Today, News, Analysis, Trading Ideas

Tech stocks

Energy

Cash / Bonds

Crypto

What&#39;s your biggest portfolio allocation right now?

Stocktwits

What's your biggest portfolio allocation right now?

Stocktwits Polls

Rivian Automotive Inc

The upcoming R2 vehicle launch is driving intense discussion, with traders weighing its potential to significantly boost sales (targeting 67,000 total vehicles this year) against production and market reception challenges.

Controversial stock sales by the CEO and CFO post-earnings have fueled debate, with skeptics citing it as a bearish signal while supporters defend them as routine tax withholdings.

Technical analysts are closely monitoring price action for signs of a double or triple bottom formation and strong support around the 200 DMA, eyeing a potential reversal after recent declines.

RIVN
Rivian Automotive Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RIVN News

RIVNRivian Automotive Inc